Biotech giant Regeneron’s (REGN) performance has been pretty ho-hum in the year so far. While Eylea sales continue to be under pressure, affecting the top line, the company finally managed to post ...

Truist on Monday lowered its price target on Regeneron (REGN) to $812 from $940, citing concerns with the company’s Eylea ...

Moving on, Regeneron’s second-quarter report was largely positive. Total revenues of $3.68 billion (up 4% YoY) beat analyst ...

Regeneron’s second quarter was marked by robust growth in key products, which the company attributed to the strong commercial ...

Regeneron Pharmaceuticals beat Wall Street estimates for second-quarter revenue and profit on Friday helped by robust demand for its blockbuster eczema treatment, Dupixent, sending its shares up ...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the top most undervalued biotech stocks to buy now. Guggenheim ...

Regeneron Pharmaceuticals delivered strong Q2 results and made net progress with its commercial portfolio and pipeline. Click here to read why REGN is a Buy.

Sanofi expects Dupixent to achieve around €22 billion in sales in 2030. For Regeneron, Dupixent generated collaboration revenues of $4.53 billion in 2024, up 19% year over year.

About Dupixent Dupixent, which was invented using Regeneron’s proprietary VelocImmune® technology, is a fully human monoclonal antibody that inhibits the signaling of the interleukin-4 (IL-4 ...

Regeneron and Sanofi on Friday said the approval covers Dupixent in people 12 and older who have CSU and remain symptomatic despite histamine-1 antihistamine treatment. The companies said the ...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) highlighted that the approval also reinforced the demonstrated safety profile of Dupixent in a broad age range of patients, from infants to elderly ...

(RTTNews) - Regeneron Pharmaceuticals Inc. (REGN) and French drug major Sanofi S.A. (SNYNF,SNY) announced Friday that the U.S. Food and Drug Administration has approved Dupixent (dupilumab) for ...